What are the recommended acute and chronic management strategies for gout, including medication choices and dosing?

Gout Treatment

Start low-dose allopurinol (≤100 mg/day, even lower if CKD stage ≥3) as first-line urate-lowering therapy for all gout patients, titrate upward to achieve serum uric acid <6 mg/dL, and provide mandatory anti-inflammatory prophylaxis (colchicine, NSAIDs, or corticosteroids) for 3-6 months during ULT initiation. 1

Acute Gout Flare Management

For acute attacks, treat as early as possible—ideally, educate patients to self-medicate at first warning symptoms 2:

First-line options (all equally effective):

• Colchicine: 1 mg loading dose, then 0.5 mg one hour later (must start within 12 hours of flare onset). Avoid in severe renal impairment and with strong P-glycoprotein/CYP3A4 inhibitors (cyclosporine, clarithromycin) 2
• NSAIDs: Full anti-inflammatory doses with proton pump inhibitor if appropriate. Avoid in severe renal impairment 1
• Corticosteroids: Oral prednisolone 30-35 mg/day for 3-5 days, or intra-articular injection after joint aspiration 2

Second-line for refractory cases:

• IL-1 blockers (canakinumab) for patients with frequent flares and contraindications to all first-line agents 2

Critical pitfall: Do NOT use high-dose colchicine—the old regimen causes significantly more side effects with no additional benefit 3. Low-dose colchicine has comparable efficacy with a placebo-like tolerability profile.

Chronic Gout Management: Urate-Lowering Therapy (ULT)

When to Start ULT

Strongly consider ULT at first gout diagnosis, particularly for 2:

• Age <40 years
• Serum uric acid >8.0 mg/dL (480 μmol/L)
• Recurrent flares, tophi, urate arthropathy, or renal stones
• Comorbidities: CKD, hypertension, heart disease, heart failure

You can start ULT during an acute flare—no need to wait for resolution 1. This conditional recommendation reflects that delaying treatment prolongs the time to achieving urate targets.

First-Line ULT: Allopurinol

Allopurinol is the preferred first-line agent over all other options due to efficacy, safety, tolerability, and cost 1:

Dosing strategy:

1. Start low: ≤100 mg/day (≤50 mg/day if CKD stage ≥3) 1
2. Titrate upward: Increase by 100 mg every 2-4 weeks 2
3. Target dose: Often requires >300 mg/day, up to maximum FDA-approved 800 mg/day 1
4. Adjust for renal function: In CKD, maximum dose should be adjusted to creatinine clearance 2

Why start low? This mitigates the risk of allopurinol hypersensitivity syndrome (AHS) and reduces flare risk during ULT initiation 1.

Alternative ULT Options

Febuxostat:

• Start at ≤40 mg/day, titrate upward 1
• Use if allopurinol target not achieved at appropriate dose, or if allopurinol not tolerated 2
• Preferred over probenecid in CKD stage ≥3 1

Probenecid:

• Start 500 mg once or twice daily, titrate upward 1
• Avoid in CKD stage ≥3 (use xanthine oxidase inhibitor instead) 1

Pegloticase:

• Strongly recommended AGAINST as first-line therapy 1
• Reserve for crystal-proven severe debilitating chronic tophaceous gout with poor quality of life when serum urate target cannot be reached with maximal doses of other agents 2

Serum Uric Acid Targets

Standard target: <6 mg/dL (360 μmol/L) for all patients, maintained lifelong 2

Lower target: <5 mg/dL (300 μmol/L) for severe gout (tophi, chronic arthropathy, frequent attacks) until total crystal dissolution 2

Avoid: <3 mg/dL long-term 2

Mandatory Flare Prophylaxis During ULT Initiation

You must provide anti-inflammatory prophylaxis when starting ULT 1:

Duration: 3-6 months minimum (not <3 months), with ongoing evaluation and continuation if flares persist 1

Options:

• Colchicine: 0.5-1 mg/day (reduce dose in renal impairment; avoid with statins due to myotoxicity risk) 2
• NSAIDs: Low-dose if not contraindicated 2
• Prednisone/prednisolone: Based on patient factors 1

Rationale: Starting ULT causes urate crystal mobilization, triggering flares in up to 80% of patients without prophylaxis. This is the most common reason for ULT discontinuation and treatment failure.

Lifestyle Modifications

Mandatory counseling 2:

• Weight loss if appropriate
• Avoid alcohol (especially beer and spirits) and sugar-sweetened drinks
• Limit heavy meals, excessive meat and seafood intake
• Encourage low-fat dairy products
• Regular exercise

Comorbidity Screening

Systematically screen for 2:

• Renal impairment
• Cardiovascular disease (coronary disease, heart failure, stroke, peripheral arterial disease)
• Hypertension, diabetes, hyperlipidemia
• Obesity, smoking

Medication adjustments 2:

• If on loop/thiazide diuretics: substitute if possible
• For hypertension: consider losartan or calcium channel blockers
• For hyperlipidemia: consider statin or fenofibrate

Treatment Algorithm Summary

1. Acute flare: Colchicine (low-dose), NSAID, or corticosteroid—start immediately
2. Initiate ULT: Allopurinol ≤100 mg/day (lower if CKD) at or near first diagnosis
3. Start prophylaxis simultaneously: Colchicine 0.5-1 mg/day for 3-6 months
4. Titrate allopurinol: Increase by 100 mg every 2-4 weeks
5. Monitor serum uric acid: Target <6 mg/dL (<5 mg/dL if severe disease)
6. Maintain lifelong: Continue ULT indefinitely to prevent crystal reaccumulation

The 2020 ACR guidelines represent the most authoritative and recent comprehensive guidance 1, with strong consensus on the "start low, go slow, treat to target" approach that has revolutionized gout management over the past decade.